Immuno-Oncology and Checkpoint Inhibition in Cervical Cancer: Bradley Monk, MD, FACS, and Ramez Eskander, MD

​ Unlike that of other gynecological malignancies, the etiology of cervical cancer is the human papillomavirus (HPV). This fact plays a role in how cervical cancer is perceived as immunogenic: T cells themselves are involved in the immune response and in the control of viral infections and the development of these tumors. In this discussion with i3 Health, Bradley Monk, MD, FACS, FACOG, Professor of Gynecologic Oncology at the University of Arizona and Creighton University, and Ramez Eskander, M...
Continue reading

Nanovaccines: A New Approach for Melanoma Treatment

Researchers have developed a nanovaccine that, when combined with antibodies and ibrutinib, shows potential as an effective treatment for melanoma. Immune checkpoint therapy, a form of cancer therapy which targets the immune system, has proven to be an effective treatment method for melanoma, the most aggressive type of skin cancer. However, immune checkpoint therapy is limited by a low response rate, severe side effects, and acquired resistance to treatment. There is a need to develop an altern...
Continue reading

Which Biomarker Modalities Best Predict Immunotherapy Response?

In order to help predict how tumors will respond to anti–PD-1 (programmed cell death 1)/PD-L1 (programmed cell death ligand-1) therapies, doctors assess patients using PD-L1 immunohistochemistry (IHC), tumor mutational burden (TMB), gene expression profiling (GEP), and multiplex immunohistochemistry/immunofluorescence (mIHC/IF). However, the diagnostic performance of these tests has not been established. To bridge this education gap, researchers conducted a systematic review to determine the acc...
Continue reading

Pembrolizumab Approved in Metastatic Small Cell Lung Cancer

Pembrolizumab (Keytruda®, Merck) has received accelerated FDA approval for patients with metastatic small cell lung cancer (SCLC) experiencing disease progression during or after platinum-based chemotherapy following at least one other previous line of therapy. Metastatic SCLC, or extensive-stage SCLC, comprises around 15% of all lung cancers and occurs primarily in heavy smokers. It carries a dismal outlook; only 5% of patients with extensive-stage SCLC live for two years after diagnosis. Appro...
Continue reading

Cancer Immunotherapy Collaborative Learning With Latha Shivakumar, PhD, CHCP

​ In the constantly evolving field of cancer immunotherapy, it is crucial that community practitioners keep abreast of the latest advances. In this interview with i3 Health, Latha Shivakumar, PhD, CHCP, discusses her poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting concerning the initiative she led at the Association of Community Cancer Centers (ACCC): collaborative learning workshops focused on best practices for immunotherapy in the community setting. What...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.